Rank | Title | Journal | Year | PubWeight™‹?› |
---|---|---|---|---|
1 | NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer. | Clin Cancer Res | 2017 | 1.03 |
2 | A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer. | Clin Cancer Res | 2017 | 0.75 |